Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ergosterol peroxide is a naturally occurring steroid derivative and small molecule isolated from various medicinal fungi, most notably *Ganoderma lucidum* (Reishi), as well as yeast, lichens, and sponges. It exhibits a broad spectrum of biological activities, including potent anticancer, anti-inflammatory, antiviral, and antimycobacterial properties. Mechanistically, it has been identified as an inhibitor of glutaminase 1 (GLS1), which disrupts cancer cell metabolism by blocking the conversion of glutamine to glutamate, and as an inhibitor of the sodium/taurocholate cotransporting polypeptide (NTCP), which is a key entry receptor for hepatitis B and D viruses. Preclinical research, primarily conducted by academic institutions such as Qiqihar Medical University and National Chiao Tung University, has demonstrated its efficacy in murine models of triple-negative breast cancer and liver cancer. The compound has shown metabolic stability and a favorable safety profile in animal studies, with no signs of toxicity at doses up to 500 mg/kg.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ergosterol peroxide.